Resurrect Bio is a plant biotechnology company that will improve the immune systems of crop species to revolutionize the agricultural industry.
Vitarka Therapeutics develops medical technology and solutions for various types of cancer. It is based in London, United Kingdom.
Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
MIRICO leads the way in high performance gas sensing intelligence using unique Laser Dispersion Spectroscopy (LDS) in any weather conditions to transform productivity and deliver a positive impact on the environment. Located in a brand new, purpose built facility on the Harwell Science & Innovation Campus near Oxford, UK, MIRICO is a spin out from the Laser Spectroscopy Group at the STFC Rutherford Appleton Laboratory. The company was established in December 2015. MIRICO’s specialist team of experts are actively designing and developing LDS to set new standards for gas sensing in challenging measurement conditions for targeted applications.
Lineat is a manufacturer of fiber tape products. The company's carbon fiber tapes are manufactured using aligned formable fiber technology. It designed a closed-loop water circulation system to improve LCA.
MitoRx Therapeutics is a biotechnology company developing novel therapeutics that reverse mitochondrial dysfunction.
Q5D is an Innovative company that automates the manufacture and assemble of wiring looms. Q5D manufactures tools to automate the production of wiring harnesses for all industrial sectors.
Atheras Analytics has developed a suite of AI-based, SaaS-delivered software tools for designing and operating Ka-band and Q/V-band satellite networks to mitigate the effects of weather and improve network and service availability.
Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
NanoSyrinx is an emerging biotechnology company developing a novel system for targeted delivery of therapeutic proteins and peptides direct to the cytosol. We are using synthetic biology approaches to develop a completely novel method for targeted drug delivery of therapeutic proteins and peptides, to the interiors of cells, to improve efficacy, safety, and economy.
AgPlus Diagnostics have developed a diagnostic platform technology that will deliver against the demanding market requirements of a true quantitative PoC product for use across a wide range of clinical applications.
Vector Photonics is a spin-out company from the University of Glasgow and is based in Glasgow, Scotland, one of the UK and world’s Optical and Photonics centres of excellence.
CytoSeek's mission is to use cell membrane augmentation technology to unlock the potential of next generation of advanced therapies. We are a spinout company from the University of Bristol. Our novel cell membrane augmentation technology enables us to add new functionalities to cell therapies including tissue specific targeting and enhanced cell survivability. CytoSeek is engaged in proof of principle studies to demonstrate enhancement of cell therapies for cancer, heart disease, osteoarthritis and diabetic wound healing. We are looking to partner with cell therapy companies to bring these products to the clinic and ultimately enhance human health.
Antiverse is a new type of antibody discovery company accelerating drug development. Its platform exists at the intersection of structural biology, machine learning, and medicine to enable breakthroughs to happen more quickly and cost-effectively. It is dedicated to engineering the future of drug development to change the course of people's lives.
Linear Diagnostics Limited (LDL) is a diagnostics company based on a novel technology that allows wide range of molecular diagnostics tests to be carried out using a simple optical system. The technology provides significant advantages over the current state of the art allowing a more rapid detection of multiple targets using a single simple reagent
Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
NanoSyrinx is an emerging biotechnology company developing a novel system for targeted delivery of therapeutic proteins and peptides direct to the cytosol. We are using synthetic biology approaches to develop a completely novel method for targeted drug delivery of therapeutic proteins and peptides, to the interiors of cells, to improve efficacy, safety, and economy.
Atelerix has a transformative technology for the storage and transport of viable cells at room temperature, overcoming the barriers and limitations presented by the current need for cryo-shipping. We do this using our patented process of encapsulating the cells in a natural hydrogel for safe shipment and storage. The cells can be recovered when needed by the addition of a gentle, cell-friendly buffer. This means: Predictability and reliability in drug discovery models and for cells used as therapies Customers can use cells and assays immediately on arrival No need for cryopreservation, nor need for cytotoxic or animal-derived supplements Cells retain their natural state and are not damaged nor altered
At Tropic Biosciences, They develop high-performing commercial varieties of tropical crops which promote grower wellbeing, consumer health, and improved sustainable environmental practices, using cutting edge non-GMO gene editing techniques.
MicrofluidX is tackling the problems of process control, scalability, and cost associated with cell bioprocessing, in particular for autologous cell and gene therapy.
Ikarovek is working on early stage assets intended for the treatment of diabetic macular edama.
Pencil Biosciences aims to develop a novel, programmable genome-modulation tool that overcomes the challenges associated with the technologies currently available.
CytoSeek's mission is to use cell membrane augmentation technology to unlock the potential of next generation of advanced therapies. We are a spinout company from the University of Bristol. Our novel cell membrane augmentation technology enables us to add new functionalities to cell therapies including tissue specific targeting and enhanced cell survivability. CytoSeek is engaged in proof of principle studies to demonstrate enhancement of cell therapies for cancer, heart disease, osteoarthritis and diabetic wound healing. We are looking to partner with cell therapy companies to bring these products to the clinic and ultimately enhance human health.
The problem of Needle Stick Injuries (NSI's) is well known throughout medical practice worldwide. However despite nearly two decades of work and legislation in the USA, Europe and other countries, the incidents of NSI's have not fallen as fast or as far as was hoped C-Major Medical was established with the sole purpose of developing a new range of safety devices that will enable, hospitals, clinics and medical practicioners everywhere to prevent NSI's.
Atelerix has a transformative technology for the storage and transport of viable cells at room temperature, overcoming the barriers and limitations presented by the current need for cryo-shipping. We do this using our patented process of encapsulating the cells in a natural hydrogel for safe shipment and storage. The cells can be recovered when needed by the addition of a gentle, cell-friendly buffer. This means: Predictability and reliability in drug discovery models and for cells used as therapies Customers can use cells and assays immediately on arrival No need for cryopreservation, nor need for cytotoxic or animal-derived supplements Cells retain their natural state and are not damaged nor altered
Procarta Biosystems Ltd., established in 2007 by the scientific founders, Dr. Michael McArthur and Professor Mervyn Bibb, is a spin-out company from the John Innes Centre, Norwich, a world renowned scientific centre of excellence in plant science and microbiology. The company was initially established through Plant Bioscience Ltd (PBL), the internationally regarded group specialising in early stage technology investment and IP management, on behalf of the JIC, the Sainsbury Laboratory and the Biotechnology and Biological Sciences Research Council. Procarta received seed funding in 2008 from the Rainbow and Iceni Seedcorn Funds and is currently headquartered on the Norwich Research Park.
Eagle Genomics is a enterprise software solutions company whose products enable the management, orchestration and exploitation of genomics and other life sciences data. They help Life Science companies get the maximum value from their R&D data and they are delivering the information architecture for the genomics era. Their suite of software products radically reduces cost and time to complete research, enabling drastic productivity improvements. Their architecture translates data sets into data assets, redefining the current paradigm in the industry, enabling the objective measurement of the value of digital assets and providing clarity on “return on information”. Their mix of expertise in biology, bioinformatics, data science and enterprise-class software engineering is unique in the field and has been applied over the last decade to solve their customers’ challenges in areas as diverse as drug development, personal hygiene and plant breeding. With global customers in the pharmaceuticals, fast moving consumer goods and agri-tech industries they understand the common challenges facing these industries in the handling of ever growing of data and information resources. Eagle Genomics is at the forefront in addressing the challenges, risks, and opportunities in delivering the enterprise information architecture for the genomics era.
Antiverse is a new type of antibody discovery company accelerating drug development. Its platform exists at the intersection of structural biology, machine learning, and medicine to enable breakthroughs to happen more quickly and cost-effectively. It is dedicated to engineering the future of drug development to change the course of people's lives.
At Tropic Biosciences, They develop high-performing commercial varieties of tropical crops which promote grower wellbeing, consumer health, and improved sustainable environmental practices, using cutting edge non-GMO gene editing techniques.
CytoSeek's mission is to use cell membrane augmentation technology to unlock the potential of next generation of advanced therapies. We are a spinout company from the University of Bristol. Our novel cell membrane augmentation technology enables us to add new functionalities to cell therapies including tissue specific targeting and enhanced cell survivability. CytoSeek is engaged in proof of principle studies to demonstrate enhancement of cell therapies for cancer, heart disease, osteoarthritis and diabetic wound healing. We are looking to partner with cell therapy companies to bring these products to the clinic and ultimately enhance human health.
Glialign is developing a novel cell therapy for peripheral nerve repair — for which current therapies are only successful in less than half of the cases and often can require grafting of a nerve from another part of the body.
MIRICO leads the way in high performance gas sensing intelligence using unique Laser Dispersion Spectroscopy (LDS) in any weather conditions to transform productivity and deliver a positive impact on the environment. Located in a brand new, purpose built facility on the Harwell Science & Innovation Campus near Oxford, UK, MIRICO is a spin out from the Laser Spectroscopy Group at the STFC Rutherford Appleton Laboratory. The company was established in December 2015. MIRICO’s specialist team of experts are actively designing and developing LDS to set new standards for gas sensing in challenging measurement conditions for targeted applications.
Atelerix has a transformative technology for the storage and transport of viable cells at room temperature, overcoming the barriers and limitations presented by the current need for cryo-shipping. We do this using our patented process of encapsulating the cells in a natural hydrogel for safe shipment and storage. The cells can be recovered when needed by the addition of a gentle, cell-friendly buffer. This means: Predictability and reliability in drug discovery models and for cells used as therapies Customers can use cells and assays immediately on arrival No need for cryopreservation, nor need for cytotoxic or animal-derived supplements Cells retain their natural state and are not damaged nor altered
Eagle Genomics is a enterprise software solutions company whose products enable the management, orchestration and exploitation of genomics and other life sciences data. They help Life Science companies get the maximum value from their R&D data and they are delivering the information architecture for the genomics era. Their suite of software products radically reduces cost and time to complete research, enabling drastic productivity improvements. Their architecture translates data sets into data assets, redefining the current paradigm in the industry, enabling the objective measurement of the value of digital assets and providing clarity on “return on information”. Their mix of expertise in biology, bioinformatics, data science and enterprise-class software engineering is unique in the field and has been applied over the last decade to solve their customers’ challenges in areas as diverse as drug development, personal hygiene and plant breeding. With global customers in the pharmaceuticals, fast moving consumer goods and agri-tech industries they understand the common challenges facing these industries in the handling of ever growing of data and information resources. Eagle Genomics is at the forefront in addressing the challenges, risks, and opportunities in delivering the enterprise information architecture for the genomics era.
Procarta Biosystems Ltd., established in 2007 by the scientific founders, Dr. Michael McArthur and Professor Mervyn Bibb, is a spin-out company from the John Innes Centre, Norwich, a world renowned scientific centre of excellence in plant science and microbiology. The company was initially established through Plant Bioscience Ltd (PBL), the internationally regarded group specialising in early stage technology investment and IP management, on behalf of the JIC, the Sainsbury Laboratory and the Biotechnology and Biological Sciences Research Council. Procarta received seed funding in 2008 from the Rainbow and Iceni Seedcorn Funds and is currently headquartered on the Norwich Research Park.
Camstech Ltd is an early stage company developing novel biochemical sensing technologies. Having graduated from the CERN Business Incubation Centre at Harwell Campus in Oxfordshire, the company is now based at STFC’s Campus Technology Hub, Daresbury Laboratory. Camstech was established in 2014 with a vision to commercialise a novel sensing technology developed by Professor Pankaj Vadgama, initially for life sciences research and subsequently for applications in biotechnology and medical diagnostics.
Cagen is a synthetic biology company.
MyoDOPA
Seed Round in 2018
MyoDOPA is develops a novel therapeutic profile providing efficient treatment.
SFH Oxford’s innovative technology healthcare products will , Deliver significantly improved care for long suffering patients.and Help all healthcare professionals involved in venous leg ulcer management deliver optimised, quality care, first time, every time. They have a number of products undergoing clinical and field trials which are already generating exciting results in real-world conditions.Their experienced leadership team has proven success in medical device technology, wound care products, manufacturing and business development.
The problem of Needle Stick Injuries (NSI's) is well known throughout medical practice worldwide. However despite nearly two decades of work and legislation in the USA, Europe and other countries, the incidents of NSI's have not fallen as fast or as far as was hoped C-Major Medical was established with the sole purpose of developing a new range of safety devices that will enable, hospitals, clinics and medical practicioners everywhere to prevent NSI's.
Pireta has developed a unique free-form process to add durable, conductive, metallic patterns to textiles without changing the fabric feel or performance. Pireta’s technology allows electronic systems to be assembled and interconnected on a wide range of fabrics, enabling a new generation of truly wearable smart garments and e-textiles.
Synthace is a digital experiment platform built for life science R&D teams to help them run more powerful experiments. It digitizes experiments from end to end: with minimal training, scientists can design and plan reproducible experiments, simulate them ahead of time, run them on their automation equipment, and automatically structure all of their experimental data and metadata in a single place. Controlled from a browser window and needing no code to operate, it makes experiments easier to run in the lab, increases the scientific value of experiments, and also makes it possible to run experiments that were previously thought impossible.
Puraffinity specialises in the design and development of precision materials, and has developed a sustainable novel adsorbent capable of removing highly challenging pollutants from contaminated water and wastewater. The technology utilises advanced supramolecular chemistry methods to functionalise sustainable materials designed to bind target chemicals. The company is at the forefront of developing solutions for overcoming imminent water quality challenges, whilst sustainable and positive environmental impact lies at the heart of the company’s ethos.
Cytox have developed a simple genetic based blood test for the assessment of risk and diagnosis of Alzheimer's Disease in the very early stages. Alzheimer's Disease affects over 26 million people world-wide and is a growing condition as people live longer. There is currently no cure for Alzheimer's Disease, but there are large international initiatives underway to find treatments with many drugs in clinical development. Cytox are commercially launching their tests in conjunction with Affymetrix (part of Thermo Fisher Scientific) to support Pharmaceutical and Biotechnology companies developing novel therapeutics.
At Tropic Biosciences, They develop high-performing commercial varieties of tropical crops which promote grower wellbeing, consumer health, and improved sustainable environmental practices, using cutting edge non-GMO gene editing techniques.
Linear Diagnostics Limited (LDL) is a diagnostics company based on a novel technology that allows wide range of molecular diagnostics tests to be carried out using a simple optical system. The technology provides significant advantages over the current state of the art allowing a more rapid detection of multiple targets using a single simple reagent
Nemesis Bioscience is a UK-based biopharmaceutical company developing products to resurrect anti-microbial therapies made ineffective by increasing microbial resistance. The company develops Nemesis Symbiotics that will make existing antibiotics work again, prevent the spread of resistance genes, and so also protect the efficacy of new antibiotics. The technology is applicable to all antibiotic classes, all known resistance mechanisms and all bacteria. Other applications include reduction of chemotherapeutic toxicity, inactivation of virulence factors, and in vivo synthesis of biofuels and therapeutics. The company was awarded the King’s College, Cambridge Entrepreneurship Award for 2014 and has filed patent applications internationally on its inventions.
The Electrospinning Company is a leading edge provider of electrospun nanofibre innovations, developing solutions to industrial challenges. They also work closely with academic research groups to develop novel nano-scale fibres and coatings for scientific research.
AgPlus Diagnostics have developed a diagnostic platform technology that will deliver against the demanding market requirements of a true quantitative PoC product for use across a wide range of clinical applications.
Keit’s microFTS® design is a Fourier Transform Infrared (FTIR) spectrometer that is smaller, lighter and more rugged than any current system. Able to perform in extreme environments, the microFTS® was originally designed for space applications where these attributes are paramount. The microFTS® offers a new gold standard for real-time liquid-state analyses in the Pharmaceutical, Chemical, Oil & Gas, and Food & Beverage industries.
MIRICO leads the way in high performance gas sensing intelligence using unique Laser Dispersion Spectroscopy (LDS) in any weather conditions to transform productivity and deliver a positive impact on the environment. Located in a brand new, purpose built facility on the Harwell Science & Innovation Campus near Oxford, UK, MIRICO is a spin out from the Laser Spectroscopy Group at the STFC Rutherford Appleton Laboratory. The company was established in December 2015. MIRICO’s specialist team of experts are actively designing and developing LDS to set new standards for gas sensing in challenging measurement conditions for targeted applications.
Jupiter Diagnostics offers a faster, cheaper way to obtain accurate blood tests. Our patent- protected reader can replace the lab, delivering multiple tests in 10 minutes, from a prick of blood, at prices a third cheaper.
Quethera is a gene therapy company dedicated to improving the future treatment of common blinding eye diseases. Our initial focus is on developing therapies to reduce progressive visual loss in glaucoma and other conditions affecting the optic nerve. Quethera is working alongside world leaders in the glaucoma field to design clinical trials capable of examining the efficacy and safety of novel therapies in patients who lose parts of their visual field at an accelerated rate (fast-progressors). The company has expertise in gene therapeutic design and development sufficient to progress its pipeline through preclinical testing and into clinical development.
Oxford Space Systems is a multi-award-winning, record-breaking venture capital backed, space tech business that's developing a new generation of deployable antennas and space structures for the global satellite industry. Using both innovative design techniques such as origami and novel proprietary materials developed by the company, OSS' structures are lighter, less complex and lower cost than alternatives in commercial demand. Founded in late 2013, OSS set a record for the space sector with it's AstroTube Boom: the fastest development of a new product from concept to successful deployment on orbit in under 30 months. Today, the 18 strong and growing OSS team is a diverse mix of international graduates and experienced space industry professionals, with over 100 years of combined space sector experience. OSS investors include a small syndicate of UK venture capital funds together US based investors, Space Angels. Oxford Space Systems has successfully completed a number of UK government supported co-developments with leading European satellite builders as well straight commercial contracts in both Asia and the US. As part of its planned expansion, OSS move into its own custom facility at the Harwell Space Cluster in August 2018, giving it the largest clean room at the cluster. The facility will meet required security standards to undertake UK government defense & security contracts. .
They are a microbiological services provider that provide our clients with a research based approach to microbiological testing, whilst recognising the client’s need for a rapid turnaround and a personalised service. We specialise in bespoke assays with a primary focus on biofilm testing. They appreciate that not all products are appropriate for standard testing assays and therefore we work closely with our clients to develop methods that are suitable for the testing of novel products. They offer an extremely customer focused service that includes regular feedback, consultancy, method development and report writing. In addition we produce conference abstracts and posters based on the data we produce.
Synthace is a digital experiment platform built for life science R&D teams to help them run more powerful experiments. It digitizes experiments from end to end: with minimal training, scientists can design and plan reproducible experiments, simulate them ahead of time, run them on their automation equipment, and automatically structure all of their experimental data and metadata in a single place. Controlled from a browser window and needing no code to operate, it makes experiments easier to run in the lab, increases the scientific value of experiments, and also makes it possible to run experiments that were previously thought impossible.
CHAIN Biotechnology is a microbiome therapeutics company with a novel drug development platform targeting chronic gut-related diseases. CHAIN is developing several therapeutic compounds targeted to the gut microbiome in the large intestine that can be delivered by our CADD technology.
NorthRow is a web-based platform that enables its users to simplify and improve the quality of risk, compliance, and anti-fraud decisions. It contains a range of features that can be used separately or in combination. It allows its users to run detailed checks on people, companies, and ID documents in order to optimize business processes, reduce risk, and help ensure compliance. The platform helps confirm identity for numerous risk factors, access multiple data sources to authenticate businesses, and verify passports, visa papers, and other documents.
Synthace is a digital experiment platform built for life science R&D teams to help them run more powerful experiments. It digitizes experiments from end to end: with minimal training, scientists can design and plan reproducible experiments, simulate them ahead of time, run them on their automation equipment, and automatically structure all of their experimental data and metadata in a single place. Controlled from a browser window and needing no code to operate, it makes experiments easier to run in the lab, increases the scientific value of experiments, and also makes it possible to run experiments that were previously thought impossible.
Spectral Edge combines patented Image Fusion tech with Deep Learning to reveal more of the color, detail and clarity in any image.
Tokamak Energy is a private company developing and accelerating the development of fusion power. It requires scientific thinking and knowledge, specialist expertise and serious determination. The company offers the smallest and most cost-effective solution. Their unique approach is centred on rapid innovation using the latest materials and technology but building on decades of scientific research and experience. Tokamak Energy focused on spherical tokamaks, pioneered at Culham because these compact devices can achieve a much higher plasma pressure for a given magnetic field than conventional tokamaks. They deploying high-temperature superconducting magnets to control the plasma within its devices. These allow high magnetic fields to be created in the confined dimensions of compact tokamaks, further improving the efficiency of the device. Tokamak Energy was founded in 2009 and is headquartered in Oxfordshire, United Kingdom.
Claresys develops and supplies lens solutions for covert surveillance. Its products include covert pinhole pan/tilt/zoom lenses for mounting on C mount 1/3” sensor cameras; and miniature pinhole camera lenses. The company also designs custom lens for long range surveillance and difficult environments, such as nuclear and high temperature fields. Its optical technologies are applied in various surveillance situations, including close surveillance in buildings and vehicles, and long distance stake-outs.
NorthRow is a web-based platform that enables its users to simplify and improve the quality of risk, compliance, and anti-fraud decisions. It contains a range of features that can be used separately or in combination. It allows its users to run detailed checks on people, companies, and ID documents in order to optimize business processes, reduce risk, and help ensure compliance. The platform helps confirm identity for numerous risk factors, access multiple data sources to authenticate businesses, and verify passports, visa papers, and other documents.
Eagle Genomics is a enterprise software solutions company whose products enable the management, orchestration and exploitation of genomics and other life sciences data. They help Life Science companies get the maximum value from their R&D data and they are delivering the information architecture for the genomics era. Their suite of software products radically reduces cost and time to complete research, enabling drastic productivity improvements. Their architecture translates data sets into data assets, redefining the current paradigm in the industry, enabling the objective measurement of the value of digital assets and providing clarity on “return on information”. Their mix of expertise in biology, bioinformatics, data science and enterprise-class software engineering is unique in the field and has been applied over the last decade to solve their customers’ challenges in areas as diverse as drug development, personal hygiene and plant breeding. With global customers in the pharmaceuticals, fast moving consumer goods and agri-tech industries they understand the common challenges facing these industries in the handling of ever growing of data and information resources. Eagle Genomics is at the forefront in addressing the challenges, risks, and opportunities in delivering the enterprise information architecture for the genomics era.
Desktop Genetics is an international biotechnology company to helps researchers discover and treat the root genetic causes of human disease. Desktop Genetics is a recognized leader in genome editing technology, staffed by a dedicated team of genome editing experts, bioinformaticians, and data scientists. The company's tools and technologies are used by organizations all over the world. It enables the work of their pharma, biotech, and academic customers working in drug discovery and functional genomics.
CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga. The programme also has potential clinical utility in non-small cell lung, breast and colon cancer.
They are a microbiological services provider that provide our clients with a research based approach to microbiological testing, whilst recognising the client’s need for a rapid turnaround and a personalised service. We specialise in bespoke assays with a primary focus on biofilm testing. They appreciate that not all products are appropriate for standard testing assays and therefore we work closely with our clients to develop methods that are suitable for the testing of novel products. They offer an extremely customer focused service that includes regular feedback, consultancy, method development and report writing. In addition we produce conference abstracts and posters based on the data we produce.
SFH Oxford’s innovative technology healthcare products will , Deliver significantly improved care for long suffering patients.and Help all healthcare professionals involved in venous leg ulcer management deliver optimised, quality care, first time, every time. They have a number of products undergoing clinical and field trials which are already generating exciting results in real-world conditions.Their experienced leadership team has proven success in medical device technology, wound care products, manufacturing and business development.
Tokamak Solutions UK Ltd. engages in providing technology for fusion neutron source to transmute nuclear waste. The company was founded in 2009 and is based in Abingdon, United Kingdom.
Microvisk Technologies is a UK based company developing Micro Electro Mechanical Sensors for the international medical market.
Procarta Biosystems Ltd., established in 2007 by the scientific founders, Dr. Michael McArthur and Professor Mervyn Bibb, is a spin-out company from the John Innes Centre, Norwich, a world renowned scientific centre of excellence in plant science and microbiology. The company was initially established through Plant Bioscience Ltd (PBL), the internationally regarded group specialising in early stage technology investment and IP management, on behalf of the JIC, the Sainsbury Laboratory and the Biotechnology and Biological Sciences Research Council. Procarta received seed funding in 2008 from the Rainbow and Iceni Seedcorn Funds and is currently headquartered on the Norwich Research Park.
Microvisk Technologies is a UK based company developing Micro Electro Mechanical Sensors for the international medical market.
P2i is the world leader in liquid-repellent nano-coating technology. The company’s revolutionary plasma process reduces the surface energy of a material so that when liquids come into contact with it, they form beads and simply roll off. P2i’s customers can improve the performance of their products by protecting them from the effects of water and other liquids without affecting their look or feel. P2i’s plasma processing machines have been sold into the textile, consumer electronics, filtration, and consumables markets.
Microvisk Technologies is a UK based company developing Micro Electro Mechanical Sensors for the international medical market.
Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms. The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.
Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms. The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.
Agilent Raman Spectroscopy’s proprietary technologies use novel variants of Raman spectroscopy. Their instruments can rapidly and accurately identify materials hidden inside objects or through opaque barriers such as plastic, coloured glass, paper and skin, or can measure the concentrations of materials in mixtures, with a high degree of accuracy. Agilent Raman Spectroscopy is formerly known as Cobalt Light Systems and is part of Agilent.
Microbial Solutions Limited offers a technology that can provide on-site treatment and disposal of MWFs which can unlock and release the replacement value of both the existing treatment technology and the associated logistics costs. The Microcycle™ technology is a powerful, patented biological degradation process that reduces waste MWFs to acceptable COD concentrations, removes toxicity and allows for the safe disposal of MWF as grey water to sewers on site. Through their offering, Microbial Solutions seeks to help their clients to cost-effectively meet their environmental responsibilities and to provide regulators with the tools to implement the regulations enshrining those responsibilities.
Procarta Biosystems Ltd., established in 2007 by the scientific founders, Dr. Michael McArthur and Professor Mervyn Bibb, is a spin-out company from the John Innes Centre, Norwich, a world renowned scientific centre of excellence in plant science and microbiology. The company was initially established through Plant Bioscience Ltd (PBL), the internationally regarded group specialising in early stage technology investment and IP management, on behalf of the JIC, the Sainsbury Laboratory and the Biotechnology and Biological Sciences Research Council. Procarta received seed funding in 2008 from the Rainbow and Iceni Seedcorn Funds and is currently headquartered on the Norwich Research Park.
CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga. The programme also has potential clinical utility in non-small cell lung, breast and colon cancer.
Orbital Optics is engages in the sale of space optical cameras for space missions in the United Kingdom and internationally. It also provides consultancy on matters concerned with imaging systems and optical payloads, as well as access to supporting ground station facilities.
Oxsensis Ltd. manufactures optical sensors for pressure, vibration, temperature, and multiple parameters. The company offers optical instrumentation for precision controls in various environments, such as car and aero engines, as well as industrial, electrical, nuclear, and space applications. It also provides hi-temp optics, optical MEMS, fiber-optic assemblies, and packaging solutions. The company’s products comprise Wave-Phire Dynamic Pressure Transducer, which is used in harsh atmospheres, such as gas turbines and other combustion environments; i-Phire 4 Channel Optical Interrogator Unit that converts the optical signal into a voltage signal, which is directly proportional to the dynamic pressure; and S-Phire, a software for combustion monitoring. It serves energy production and emissions monitoring, transport, and high temperature equipment health monitoring markets. The company was incorporated in 2003 and is based in Didcot, the United Kingdom.
CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga. The programme also has potential clinical utility in non-small cell lung, breast and colon cancer.
Leveraging the extensive knowledge of GSK's Biotransformation and Natural Products scientific team, Novacta Biosystems Ltd was founded in 2003. In the following 5 years, Novacta successfully adopted a dual business model, whereby it developed a biocatalysis and microbial pathway engineering service business, that supported its efforts to build an infectious disease therapeutic pipeline.
Alopa is a pioneer and leader in the design, development, and deployment of infrastructure software solutions for end-to-end activation, management, and assurance of digital services over cable. Alopa Networks has been an industry driver in developing operations support software (OSS) solutions for broadband service providers that accelerate time-to-market for advanced network-based services and applications, including Internet telephone (VoIP), differentiated access, security, multimedia, and more. Alopa's combined family of products automates the complete life cycle of subscriber acquisition and service management by facilitating service creation, deployment, and assurance and security functions while, at the same time, accelerating revenue and lowering operating and capital expenses. Its flagship Alopa MetaServ(TM) platform is currently the only industry solution that automates the entire subscriber life cycle -- from equipment qualification through service creation and activation to customer support -- and integrates all layers of the IT infrastructure, including billing, order entry, customer care, and network management. It also provides secure provisioning for both PacketCable(TM) and CableHome(TM) networks, offering a framework for VoIP, multimedia services, and interactive gaming.